Xilio Therapeutics, Inc. (XLO) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+3965.9%

$324.87

vs $7.99 price

Levered DCF

$163.07

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

-2.75

Distress zone

Rating

B-

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-2.14×	-0.88×	-0.2×	-0.84×	-1.18×	-0.15×	-0.38×
P/B	2.12×	2.9×	0.41×	0.7×	0.48×	-1.59×	0.17×
P/S	1.71×	8.05×	0×	0×	0×	0×	0×
EV / EBITDA	1.66×	-0.07×	0.23×	0.31×	1.19×	-0.21×	1.39×
Gross margin	96.5%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	-95.9%	-954.9%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	-80.1%	-918.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	2.58×	2.21×	3.02×	5.89×	15.85×	0.93×	9.81×
Debt / equity	0.2×	0.46×	0.34×	0.19×	0.11×	-4.14×	0.48×
Interest coverage	0×	-605.82×	0×	0×	-125.07×	-90.94×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-99.3%	-331.0%	-207.5%	-83.5%	-40.9%	1044.8%	-45.0%
Return on invested capital	-42.1%	-134.6%	-160.4%	-71.0%	-35.8%	-318.3%	-33.1%
Return on assets	-22.6%	-81.9%	-125.4%	-63.4%	-34.2%	-152.0%	-27.6%
Free cash flow yield	-7.4%	-36.0%	-457.0%	-105.3%	-91.2%	-456.8%	-283.4%
Earnings yield	-46.8%	-114.0%	-505.2%	-119.7%	-84.5%	-658.9%	-264.3%
Enterprise value	-$55.7M	$4M	-$17.1M	-$26.7M	-$87.6M	$11M	-$23.7M
Net debt / EBITDA	3.9×	0.81×	0.43×	1.16×	2.41×	-0.05×	1.77×
Cash conversion cycle (days)	-709	0	0	0	-766	-1,866	-3,829